Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
AIM

AIM ImmunoTech (AIM) stock: insider trades, news & valuation

Health Care · Quiet
Close · Oct 9, 2026 $0.18 +0.0% on the day -92.9% over 12 months 52-week range $0.17 – $2.68

Share price and insider trades

AIM closeInsider buyInsider sale
0123NovDecJan 2026FebMarAprMayJunJulAugSepOctEEarnings release filed 2026-05-19EEarnings release filed 2026-08-10Bought $1,298 on 2026-09-14 · Thomas K EquelsBought $2,310 on 2026-09-16 · Thomas K EquelsBought $4,840 on 2026-09-15 · Thomas K EquelsBought $5,040 on 2026-09-17 · Thomas K Equels
Bought, 12 months$0
Sold, 12 months$0
Insiders buying0
Insiders selling0

AIM ImmunoTech insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 0 sold $0 of AIM stock on the open market.

AIM insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q3 2026: $13K bought (4 trades)$13KQ3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026$13K4—0

Valuation, profit and volume

P/E (trailing)n/aSector median 24.7
Market value$7.2MBiotechnology
Profit margin0.0%Revenue growth +4.0%
Volume vs. 50-day0.1×Last 5 sessions
Insiders' paper profit−$2KOn all tracked purchases -16.1%

Summary

No open-market purchases or sales by AIM ImmunoTech Inc. insiders were reported in the past 12 months.

AIM earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Aug 10, 2026 +16.0% None -13.8%S&P -0.3% -8.0%
May 19, 2026 -21.2% None -39.0%S&P +0.4% +52.0%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

AIM stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Sep 18SEC Thomas K EquelsCEO, President Buy 24,000126,822 held (+23%) $0.21 $5K -14.3% —
Sep 17SEC Thomas K EquelsCEO, President Buy 11,000102,822 held (+12%) $0.21 $2K -14.3% —
Sep 16SEC Thomas K EquelsCEO, President Buy 22,00091,822 held (+32%) $0.22 $5K -18.2% —
Sep 15SEC Thomas K EquelsCEO, President Buy 5,90069,822 held (+9%) $0.22 $1K -18.2% —

Insiders at AIM ImmunoTech Inc.

InsiderBoughtSoldLast filingScore
Thomas K EquelsCEO, President $13K — Sep 18, 2026 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • SLBTSL Science Holding Ltd$10329.90B bought
  • KODKodiak Sciences Inc.$157M bought
  • ADRXADARx Pharmaceuticals, Inc.$87.7M bought
  • ATTOAttovia Therapeutics, Inc.$72.9M bought
  • MPLTMapLight Therapeutics, Inc.$65.5M bought
  • AVRAnteris Technologies Global Corp.$40.4M bought

AIM stock: common questions

Are AIM ImmunoTech Inc. insiders buying AIM stock?

In the past 12 months, 0 insiders reported open-market purchases of AIM worth $0. The latest was CEO, President Thomas K Equels bought $5K of AIM at $0.21 — raises the stake by 23%.

Are AIM ImmunoTech Inc. insiders selling AIM stock?

0 insiders reported sales worth $0 over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is AIM's 52-week range?

Over the past year AIM has traded between $0.17 and $2.68. It last closed at $0.18 on Oct 9, 2026.